A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant

Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies – 90Y-ibritumomab tiuxetan is expensive and 131I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labell...

Full description

Bibliographic Details

Main Authors:	Jew, Win Kuan, Chiong, Soon Law, Xiang, Qi Wong, Ching, Tiong Ko, Zool, Hilmi Awang, Lee, Ping Chew, Kian-Meng, Chang
Format:	Article
Language:	en
Published:	Elsevier Ltd. 2016
Subjects:	RM Therapeutics. Pharmacology
Online Access:	http://ir.unimas.my/id/eprint/12763/1/A%20pioneerexperienceinMalaysiaonIn-houseRadio-labelling%28abstract%29.pdf http://ir.unimas.my/id/eprint/12763/ https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979287754&partnerID=40&md5=f2be2c3bb10247c1d16648a573219e73 http://dx.doi.org/10.1016/j.apradiso.2016.07.016
Tags:	Add Tag No Tags, Be the first to tag this record!